依布硒预防噪声性听力损失的安全性与有效性:一项随机双盲安慰剂对照2期试验
这项在佛罗里达大学开展的单中心随机双盲安慰剂对照2期试验,将83名18-31岁健康成人随机分配接受依布硒200 mg、400 mg、600 mg或安慰剂口服每日两次共4天。主要终点为校准声音挑战后15分钟4 kHz平均暂时性阈移。400 mg组TTS较安慰剂组显著降低68%,200 mg和600 mg组分别非显著降低21%和7%。依布硒各剂量耐受性良好。
要点
- 依布硒400 mg每日两次较安慰剂显著降低4 kHz暂时性阈移68%。
- 200 mg和600 mg组TTS较安慰剂分别非显著降低21%和7%。
- 依布硒各剂量耐受性良好,血液学、血清化学和放射学评估无显著组间差异。
核心结论
- 作者认为,依布硒400 mg每日两次在预防噪声诱导的暂时性阈移方面安全有效。
- 作者认为这些数据支持GPx1活性在急性噪声性听力损失中的作用。
研究设计与样本
- 单中心、随机、双盲、安慰剂对照2期试验,在佛罗里达大学开展。
- 纳入18-31岁健康成人83名,按1:1:1:1随机分配接受依布硒200 mg(n=22)、400 mg(n=20)、600 mg(n=21)或安慰剂(n=20)口服每日两次共4天,自校准声音挑战前2天开始。
- 主要终点为校准声音挑战后15分钟纯音测听测量的4 kHz平均暂时性阈移(TTS)。
- 所有接受校准声音挑战且至少接受一剂研究药物的参与者纳入有效性分析;所有随机分配患者纳入安全性分析。
主要发现
- 4 kHz平均TTS在依布硒400 mg组为1.32 dB(SE 0.91),安慰剂组为4.07 dB(SE 0.90),差异为-2.75 dB(95% CI -4.54至-0.97;p=0.0025),显著降低68%。
- 4 kHz TTS在依布硒200 mg组为3.23 dB(SE 0.91),较安慰剂组4.07 dB(SE 0.90)非显著降低21%,差异-0.84 dB(95% CI -2.63至0.94;p=0.3542)。
- 4 kHz TTS在依布硒600 mg组为3.81 dB(SE 0.90),较安慰剂组4.07 dB(SE 0.90)非显著降低7%,差异-0.27(95% CI -2.03至1.50;p=0.7659)。
- 依布硒各剂量耐受性良好,依布硒组与安慰剂组在任何血液学、血清化学或放射学评估中均未见显著差异。
关键数值与推荐
- 与安慰剂组相比,依布硒剂量组TTS降低50%被判定为具有临床相关性。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Noise-induced hearing loss is a leading cause of occupational and recreational injury and disease, and a major determinant of age-related hearing loss. No therapeutic agent has been approved for the prevention or treatment of this disorder. In animal models, glutathione peroxidase 1 (GPx1) activity is reduced after acute noise exposure. Ebselen, a novel GPx1 mimic, has been shown to reduce both temporary and permanent noise-induced hearing loss in preclinical studies. We assessed the safety and efficacy of ebselen for the prevention of noise-induced hearing loss in young adults in a phase 2 clinical trial. METHODS: In this single-centre, randomised, double-blind, placebo-controlled phase 2 trial, healthy adults aged 18-31 years were randomly assigned (1:1:1:1) at the University of Florida (Gainsville, FL, USA) to receive ebselen 200 mg, 400 mg, or 600 mg, or placebo orally twice daily for 4 days, beginning 2 days before a calibrated sound challenge (4 h of pre-recorded music delivered by insert earphones). Randomisation was done with an allocation sequence generated by an independent third party. The primary outcome was mean temporary threshold shift (TTS) at 4 kHz measured 15 min after the calibrated sound challenge by pure tone audiometry; a reduction of 50% in an ebselen dose group compared with the placebo group was judged to be clinically relevant. All participants who received the calibrated sound challenge and at least one dose of study drug were included in the efficacy analysis. All randomly assigned patients were included in the safety analysis. This trial is registered with ClinicalTrials.gov, number NCT01444846. FINDINGS: Between Jan 11, 2013, and March 24, 2014, 83 participants were enrolled and randomly assigned to receive ebselen 200 mg (n=22), 400 mg (n=20), or 600 mg (n=21), or placebo (n=20). Two participants in the 200 mg ebselen group were discontinued from the study before the calibrated sound challenge because they no longer met the inclusion criteria; these participants were excluded from the efficacy analysis. Mean TTS at 4 kHz was 1·32 dB (SE 0·91) in the 400 mg ebselen group compared with 4·07 dB (0·90) in the placebo group, representing a significant reduction of 68% (difference -2·75 dB, 95% CI -4·54 to -0·97; p=0·0025). Compared with placebo, TTS at 4 kHz was non-significantly reduced by 21% in the 200 mg ebselen group (3·23 dB [SE 0·91] vs 4·07 dB [0·90] in the placebo group; difference -0·84 dB, 95% CI -2·63 to 0·94; p=0·3542) and by 7% in the 600 mg ebselen group (3·81 dB [0·90] vs 4·07 dB [0·90] in the placebo group; difference -0·27, 95% CI -2·03 to 1·50; p=0·7659). Ebselen treatment was well tolerated across all doses and no significant differences were seen in any haematological, serum chemistry, or radiological assessments between the ebselen groups and the placebo group. INTERPRETATION: Treatment with ebselen was safe and effective at a dose of 400 mg twice daily in preventing a noise-induced TTS. These data lend support to a role of GPx1 activity in acute noise-induced hearing loss. FUNDING: Sound Pharmaceuticals.
引用
- Kil J, Lobarinas E, Spankovich C, et al. Safety and efficacy of ebselen for the prevention of noise-induced hearing loss: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2017. PMID: 28716314. doi:10.1016/S0140-6736(17)31791-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。